Metalloproteinase inhibitors
OwnerMatti Lepisto, Magnus Munck Af Rosenscholdinventors
Life of this patent
Estimating the term…
Abstract
Compounds of the formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12, wherein R5 is a bicyclic group. 1
Claims18
A compound of the formula I or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof
- 134
- wherein
- X is selected from NR1, O, S;
- Y1 and Y2 are independently selected from O, S;
- Z is selected from NR2, O, S;
- m is 0 or 1;
- A is selected from a direct bond, (C1-6)alkyl, (C1-6) alkenyl, (C1-6)haloalkyl, or (C1-6)heteroalkyl containing a hetero group selected from N, O, S, SO, SO2 or containing two hetero groups selected from N, O, S, SO, SO2 and separated by at least two carbon atoms;
- R1 is selected from H, alkyl, haloalkyl;
- R2 is selected from H, alkyl, haloalkyl;
- R3 and R6 are independently selected from H, halogen (preferably F), alkyl, haloalkyl, alkoxyalkyl, heteroalkyl, cycloalkyl, aryl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, heteroalkyl-cycloalkyl, heteroalkyl-heterocycloalkyl, cycloalkyl-alkyl, cycloalkyl-heteroalkyl, heterocycloalkyl-alkyl, heterocycloalkyl-heteroalkyl, alkylaryl, heteroalkyl-aryl, heteroaryl, alkylheteroaryl, heteroalkyl-heteroaryl, arylalkyl, aryl-heteroalkyl, heteroaryl-alkyl, heteroaryl-heteroalkyl, bisaryl, aryl-heteroaryl, heteroaryl-aryl, bisheteroaryl, cycloalkyl or heterocycloalkyl comprising 3 to 7 ring atoms, wherein the alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl radicals may be optionally substituted by one or more groups independently selected from hydroxy, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, carboxy, carboxyalkyl, alkylcarboxy, amino, N-alkylamino, N,N-dialkylamino, alkylamino, alkyl(N-alkyl)amino, alkyl(N,N-dialkyl)amino, amido, N-alkylamido, N,N-dialkylamido, alkylamido, alkyl(N-alkyl)amido, alkyl(N,N-dialkyl)amido, alkylcarbamate, alkylcarbamide, thiol, sulfone, sulfonamino, alkylsulfonamino, arylsulfonamino, sulfonamido, haloalkyl sulfone, alkylthio, arylthio, alkylsulfone, arylsulfone, aminosulfone, N-alkylaminosulfone, N,N-dialkylaminosulfone, alkylaminosulfone, arylaminosulfone, cyano, alkylcyano, guanidino, N-cyano-guanidino, thioguanidino, amidino, N-aminosulfon-amidino, nitro, alkylnitro, 2-nitro-ethene-1,1-diamine;
- R4 is selected from H, alkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, haloalkoxy, aminoalkyl, amidoalkyl, thioalkyl;
- R5 is a bicyclic or tricyclic group comprising two or three ring structures each of 3 to 7 ring atoms independently selected from cycloalkyl, aryl, heterocycloalkyl or heteroaryl, with each ring structure being independently optionally substituted by one or more substituents independently selected from halogen, thiolo, thioalkyl, hydroxy, alkylcarbonyl, haloalkoxy, amino, N-alkylamino, N,N-dialkylamino, cyano, nitro, alkyl, haloalkyl, alkoxy, alkyl sulfone, alkylsulfonamido, haloalkyl sulfone, alkylamido,alkylcarbamate, alkylcarbamide, carbonyl, carboxy, wherein any alkyl radical within any substituent may itself be optionally substituted by one or more groups independently selected from halogen, hydroxy, amino, N-alkylamino, N,N-dialkylamino, alkylsulfonamino, alkylcarboxyamino, cyano, nitro, thiol, alkylthiol, alkylsulfono, alkylaminosulfono, alkylcarboxylate, amido, N-alkylamido, N,N-dialkylamido, alkylcarbamate, alkylcarbamide, alkoxy, haloalkoxy, carbonyl, carboxy;
- R5 is a bicyclic or tricyclic group wherein each ring structure is joined to the next ring structure by a direct bond, by —O—, by —S—, by —NH—, by (C1-6)alkyl, by (C1-6)haloalkyl, by (C1-6)heteroalkyl, by (C1-6)alkenyl, by (C1-6)alkynyl, by sulfone, by carboxy(C1-6)alkyl, or is fused to the next ring structure;
- Optionally R2 and R4 may join to form a ring comprising up to 7 ring atoms or R3 and R6 may join to form a ring comprising up to 7 ring atoms;
- Provided that:
- when X is NR1, R1 is H, Y1 is O, Y2 is O, Z is O, m is 0, A is a direct bond, R3 is H, R4 is H and R6 is H, then R5 is not n-methylbenzimidazole, or 5-(benzo[1,3]dioxol-5-yl;
- when X is S, at least one of Y1 and Y2 is O, m is 0, A is a direct bond, R3 is H or methyl, R6 is H or methyl, then R5 is not quinoxaline-1,4-dioxide.
A compound as claimed in any of the preceding claims or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, wherein R5 is a bicyclic group comprising two optionally substituted 5 or 6 membered rings independently selected from cycloalkyl, aryl, heterocycloalkyl or heteroaryl.
A compound as claimed in any of the preceding claims or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, wherein R6 is H, alkyl, hydroxyalkyl, aminoalkyl, cycloalkyl-alkyl, alkyl-cycloalkyl, arylalkyl, alkylaryl, heteroalkyl, heterocycloalkyl-alkyl, alkyl-heterocycloalkyl, heteroaryl-alkyl or heteroalkyl-aryl.
A compound of the formula Ib or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof
- Formula Ib:
- 135
- wherein
- X is selected from NR1, O, S;
- Y1 and Y2 are independently selected from O, S;
- Z is selected from NR2, O, S;
- m is 0 or 1;
- A is selected from a direct bond, (C1-6)alkyl, (C1-6)haloalkyl, or (C1-6) heteroalkyl containing a hetero atom selected from O, S;
- B is selected from a direct bond, —O—, —S—, —NH—, amide, carbamate, carbonyl, (C1-6)alkyl, (C1-6)haloalkyl, (C2-6)alkenyl, (C2-6)alkynyl, or (C1-6)heteroalkyl containing a hetero atom selected from O, S;
- R1 is selected from H, (C1-3)alkyl or (C1-3)haloalkyl;
- R2 is selected from H, (C1-3)alkyl or (C1-3)haloalkyl;
- R3 is selected from H, (C1-3)alkyl or (C1-3)haloalkyl;
- R4 is selected from H, (C1-3)alkyl or (C1-3)haloalkyl;
- R6 is selected from H, alkyl, heteroalkyl, (C3-7)cycloalkyl, (C3-7)heterocycloalkyl, (C3-7)aryl, (C3-7)heteroaryl, alkyl-(C3-7)cycloalkyl, alkyl-(C3-7)heterocycloalkyl, alkyl-(C3-7)aryl, alkyl-(C3-7)heteroaryl, heteroalkyl-(C3-7)cycloalkyl, heteroalkyl-(C3-7)heterocycloalkyl, heteroalkyl-(C3-7)aryl, heteroalkyl-(C3-7)heteroaryl, (C3-7)cycloalkyl-alkyl, (C3-7)heterocycloalkyl-alkyl, (C3-7)ary-alkyl, (C3-7)heteroaryl-alkyl, (C3-7)cycloalkyl-heteroalkyl, (C3-7)heterocycloalkyl-heteroalkyl, (C3-7)aryl-heteroalkyl, (C3-7)heteroaryl-heteroalkyl;
- in R6 the alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl radicals may be optionally substituted by one or more groups independently selected from hydroxy, alkyl,halo, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, carboxy, carboxyalkyl, alkylcarboxy, amino, N-alkylamino, N,N-dialkylamino, alkylamino,alkyl(N-alkyl)amino, alkyl(N,N-dialkyl)amido, amido, N-alkylamido, N,N-dialkylamido, alkylamido, alkyl(N-alkyl)amido, alkyl(N,N-dialkyl)amido, alkylcarbamate, alkylcarbamide, thiol, sulfone, sulfonamino, alkylsulfonamino, arylsulfonamino, sulfonamido, haloalkyl sulfone, alkylthio, arylthio, alkylsulfone, arylsulfone, aminosulfone, N-alkylaminosulfon, N,N-dialkylaminosulfone, alkylaminosulfone, arylaminosulfone, cyano, alkylcyano, guanidino, N-cyano-guanidino, thioguanidino, amidino, N-aminosulfon-amidino, nitro, alkylnitro, 2-nitro-ethene-1,1-diamine;
- either G1 is a monocyclic group and G2 is selected from a monocyclic group and a bicyclic group, or G1 is a bicyclic group and G2 is a monocyclic group, wherein the monocyclic group comprises one ring structure and the bicyclic group comprises two ring structures either fused together or joined together by B as defined above, each ring structure having up to 7 ring atoms and being independently selected from cycloalkyl, aryl, heterocycloalkyl or heteroaryl, with each ring structure being independently optionally substituted by one or more substituents independently selected from halogen, thiolo, thioalkyl, hydroxy, alkylcarbonyl, haloalkoxy, amino, N-alkylamino, N,N-dialkylamino, cyano, nitro, alkyl, haloalkyl alkoxy, alkyl sulfone,alkylsulfonamido, haloalkyl sulfone, alkylamido,alkylcarbamate, alkylcarbamide, wherein any alkyl radical-within any substituent may itself be optionally substituted by one or more groups independently selected from halogen, hydroxy, amino, N-alkylamino, N,N-dialkylamino, alkylsulfonamino, cyano, nitro, thiol, alkylthiol, alkylsulfono, alkylaminosulfono, alkylcarboxylate, amido, N-alkylamido, N,N-dialkylamido, alkylcarbamate, alkylcarbamide,alkoxy, haloalkoxy;
- Optionally R3 and R6 may join to form a ring comprising up to 7 ring atoms.
A compound of the formula Ic or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof
- Formula Ic:
- 136
- wherein
- B is selected from a direct bond, acetylene, —O—, —NH—, —S—, or CH2O;
- R6 is selected from H, alkyl, heteroalkyl, (C3-7)cycloalkyl, (C3-7)heterocycloalkyl, (C3-7)aryl, (C3-7)heteroaryl, alkyl-(C3-7)cycloalkyl, alkyl-(C3-7)heterocycloalkyl, alkyl-(C3-7)aryl, alkyl-(C3-7)heteroaryl, heteroalkyl-(C3-7)cycloalkyl, heteroalkyl-(C3-7)heterocycloalkyl, heteroalkyl-(C3-7)aryl, heteroalkyl-(C3-7)heteroaryl, (C3-7)cycloalkyl-alkyl, (C3-7)heterocycloalkyl-alkyl, (C3-7)ary-alkyl, (C3-7)heteroaryl-alkyl, (C3-7)cycloalkyl-heteroalkyl, (C3-7)heterocycloalkyl-heteroalkyl, (C3-7)aryl-heteroalkyl, (C3-7)heteroaryl-heteroalkyl;
- in R6 the alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl radicals may be optionally substituted by one or more groups independently selected from hydroxy, alkyl, halo, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, carboxy, carboxyalkyl, alkylcarboxy, amino, N-alkylamino, N,N-dialkylamino, alkylamino,alkyl(N-alkyl)amino, alkyl(N,N-dialkyl)amino, amido, N-alkylamido, N,N-dialkylamido, alkylamido, alkyl(N-alkyl)amido, alkyl(N,N-dialkyl)amido, alkylcarbamate, alkylcarbamide, thiol, sulfone, sulfonamino, alkylsulfonamino, arylsulfonamino, sulfonamido, haloalkyl sulfone, alkylthio, arylthio, alkylsulfone, arylsulfone, aminosulfone, N-alkylaminosulfon, N,N-dialkylaminosulfone, alkylaminosulfone, arylaminosulfone, cyano, alkylcyano, guanidino, N-cyano-guanidino, thioguanidino, amidino, N-aminosulfon-amidino, nitro, alkylnitro, 2-nitro-ethene-1,1-diamine;
- either G1 is a monocyclic group and G2 is selected from a monocyclic group and a bicyclic group, or G1 is a bicyclic group and G2 is a monocyclic group, wherein the monocyclic group comprises one ring structure and the bicyclic group comprises two ring structures either fused together or joined together by B as defined above, each ring structure having up to 7 ring atoms and being independently selected from cycloalkyl, aryl, heterocycloalkyl or heteroaryl, with each ring structure being independently optionally substituted by one or more substituents independently selected from halogen, thiolo, thioalkyl, hydroxy, alkylcarbonyl, haloalkoxy, amino, N-alkylamino, N,N-dialkylamino, cyano, nitro, alkyl, haloalkyl alkoxy, alkyl sulfone,alkylsulfonamido, haloalkyl sulfone, alkylamido,alkylcarbamate, alkylcarbamide, wherein any alkyl radical within any substituent may itself be optionally substituted by one or more groups independently selected from halogen, hydroxy, amino, N-alkylamino, N,N-dialkylamino, alkylsulfonamino, cyano, nitro, thiol, alkylthiol, alkylsulfono, alkylaminosulfono, alkylcarboxylate, amido, N-alkylamido, N,N-dialkylamido, alkylcarbamate, alkylcarbamide,alkoxy, haloalkoxy.
A compound of the formula Id or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof
- Formula Id:
- 137
- wherein
- B is selected from a direct bond, O or CH2O;
- G1 is a monocyclic or bicyclic group comprising at least one five or six membered aryl ring;
- R6 is H, alkyl, hydroxyalkyl, aminoalkyl, alkyl-carbamic acid alkyl ester, alkyl-alkyl-urea, alkylsulfonyl-alkyl, N-alkyl-alkylsulfonamide, heteroaryl-alkyl;
- L is selected from H, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkylamino, amido, alkylamido, alkylcarbamate, alkylcarbamide, alkylsulfono, alkylsulfonamido,nitro, cyano, halo;
- or L is a group:
- T—U—V—
- wherein V is attached to G1 and V is selected from CH2, O, NCO, NCOO, NCON or NSO2;
- U is (C1-5)alkyl;
- T is selected from hydroxy, alkoxy, cyano, amino, alkylamino, alkylsulfono, alkylsulfonamide, alkylcarbamate, alkylacarbamide, alkylamide, imidazolyl, triazolyl or pyrollidon.
A method of treating a metalloproteinase mediated disease or condition which comprises administering to a warm-blooded animal a therapeutically effective amount of a compound of the formulae I or Ib or Ic or Id or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
Use of a compound of the formulae I or Ib or Ic or Id or a pharmaceutically acceptable salt or in vivo hydrolysable precursor thereof in the preparation of a medicament for use in the treatment of a disease or condition mediated by one or more metalloproteinase enzymes.
Dependencies are inferred from the claim text.